Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Receives Consensus Recommendation of “Buy” from Analysts

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) has been assigned an average recommendation of “Buy” from the seven research firms that are presently covering the stock, MarketBeat reports. One research analyst has rated the stock with a hold recommendation, five have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $54.20.

TARS has been the topic of a number of research analyst reports. Oppenheimer boosted their target price on Tarsus Pharmaceuticals from $63.00 to $65.00 and gave the stock an “outperform” rating in a research report on Thursday, November 14th. The Goldman Sachs Group upped their price objective on Tarsus Pharmaceuticals from $36.00 to $41.00 and gave the stock a “neutral” rating in a report on Friday, November 15th. Finally, William Blair raised shares of Tarsus Pharmaceuticals to a “strong-buy” rating in a report on Friday, August 30th.

Hedge Funds Weigh In On Tarsus Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Quest Partners LLC purchased a new position in Tarsus Pharmaceuticals during the second quarter valued at approximately $61,000. Canada Pension Plan Investment Board purchased a new position in shares of Tarsus Pharmaceuticals in the 2nd quarter valued at $114,000. Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of Tarsus Pharmaceuticals by 33.4% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,109 shares of the company’s stock worth $166,000 after acquiring an additional 1,530 shares in the last quarter. FMR LLC lifted its stake in shares of Tarsus Pharmaceuticals by 236.6% during the 3rd quarter. FMR LLC now owns 5,032 shares of the company’s stock worth $166,000 after purchasing an additional 3,537 shares during the last quarter. Finally, Dark Forest Capital Management LP bought a new stake in Tarsus Pharmaceuticals during the second quarter valued at about $202,000. Institutional investors own 90.01% of the company’s stock.

Tarsus Pharmaceuticals Stock Performance

NASDAQ TARS opened at $50.84 on Friday. The company has a quick ratio of 5.38, a current ratio of 5.42 and a debt-to-equity ratio of 0.30. Tarsus Pharmaceuticals has a twelve month low of $15.60 and a twelve month high of $52.99. The business has a 50-day moving average price of $40.37 and a 200-day moving average price of $33.19. The firm has a market cap of $1.94 billion, a price-to-earnings ratio of -13.34 and a beta of 1.00.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.